2014

Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists

    SHANGHAI, China, March 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech, the
 leading pharmaceutical, biotechnology and medical device R&D outsourcing
 company with operations in China and the United States, was very honored to
 have Professor David W. C. MacMillan, a renowned researcher from Princeton
 University, as a WuXi PharmaTech Science Seminar Series speaker who
 delivered a lecture to the company's young scientists on March 25, 2008.
 
     (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
 
     Aiming to keep the company's young scientists abreast of the latest
 drug R&D knowledge and technologies, the WuXi PharmaTech Science Seminar
 Series is a monthly program that invites accomplished researchers from
 academia and the industry to share their wealth of experience and expertise
 with the company's scientists.
 
     Dr. David MacMillan obtained his undergraduate degree from Glasgow
 University, and in 1990 moved to the University of California, Irvine,
 where he obtained his Ph.D. under the direction of Larry E. Overman.
 Following postdoctoral research with David A. Evans at Harvard University,
 Dr. MacMillan began his independent research career at the University of
 California, Berkeley, in 1998. In 2000, he joined the department of
 chemistry at Caltech, and was promoted to full professor in 2003. He was
 appointed to the A. Barton Hepbum Chair of Chemistry and Director of the
 Merck Center for Catalysis at Princeton University in June 2006.
 
     Dr. MacMillan is a leader in the currently active area of asymmetric
 organocatalysis. His numerous accomplishments have found widespread
 industrial application and his success is evidenced by the numerous awards
 and honors he has received from professional associations like the Royal
 Society of Chemistry, the American Chemical Society and the industry.
 
     "We are very honored and privileged to have Dr. MacMillan as one of our
 seminar speakers. His remarkable achievements in the field of organic
 synthesis will motivate our young scientists," said Dr. Shuhui Chen, Chief
 Scientific Officer of the company. "As a research-driven company serving
 global pharmaceutical, biotechnology and medical device companies, we
 believe science has no boundary. We will continue inviting heavy-weight
 speakers to WuXi so that our scientists can learn from the best, and
 ultimately provide better services to our customers."
 
     About WuXi PharmaTech
 
     WuXi PharmaTech, headquartered in Shanghai, China, is a leading global
 pharmaceutical, biotechnology and medical device R&D outsourcing company
 with operations in China and the U.S. As a research-driven and
 customer-focused company, WuXi PharmaTech provides a broad and integrated
 portfolio of laboratory and manufacturing services throughout the drug and
 medical device R&D process to pharmaceutical, biotechnology and medical
 device companies. Our services are designed to assist our global customers
 in shortening the time and lowering the cost of drug and medical device R&D
 by providing cost- effective and efficient outsourcing solutions. For more
 information, please visit: http://www.wuxipharmatech.com .
 
 
For more information, please contact: Sherry Shao Tel: +86-21-5046-4002 Email: pr@pharmatechs.com

SOURCE WuXi PharmaTech

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.